Atlas Trials

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Clinical trial NCT07318636 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07318636
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Resectable Non-small Cell Lung Cancer
Start date
2026-01-20
Primary completion
2026-12-30
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.